Be the first person to write a business review for Titan Pharmaceuticals, Inc.

TolerRx, Inc. company develops therapies to treat patients with autoimmune diseases, including Type I diabetes and rheumatoid arthritis. Organ transplant rejection is also a target. The company's treatments induce immunological tolerance, or teach a body's immune system to recognize its own tissues and prevent it from attacking the tissue and causing disease. TolerRx has five autoimmune and two cancer/chronic viral drugs in the pipeline. The immune drugs include treatments for Type I diabetes, psoriasis, rheumatoid arthritis, and lupus. TolerRx was founded in 2000 by Herman Waldmann and Douglas J. Ringler.

Tongjitang Chinese Medicines Company was founded in 1995 and is headquartered in Shenzhen, the People's Republic of China. Tongjitang Chinese Medicines Company, through its subsidiaries, engages in the development, manufacture, marketing, and sale of Chinese medicines, nutritional products, and Tibetan recipe-originated plant-based medicines in the People’s Republic of China. The company also involves in the wholesale and retail of medicines. It offers Xianling Gubao for the treatment of osteoporosis, osteoarthritis, ischemic bone necrosis, and bone fractures; Zaoren Anshen Capsules for the treatment of insomnia; and moisturizing and anti-itching Capsules for the treatment of inflammatory skin conditions. The company also produces and sells Dianbaizhu Syrup for the treatment of vertigo; Compound Glycyrrhiza oral solution for the treatment of upper respiratory infections; Jiao Ti Guo Jiao Bi Capsules that prevent gastritis and ulcers; Bu Shen Yi Lao capsules, which improve memory, breathing, hearing, and general malaise; Xin Nao Kang capsules for the treatment of stroke and coronary artery disease; Jincishen Mixture used as an ancillary to treatment of cancer; Heiguteng capsules for the treatment of rheumatoid arthritis; Chongcao Qingfei capsules for the treatment of Chronic Obstructive Pulmonary Disease; Fengshi Gutong capsules for the treatment of rheumatoid arthritis; and Jingshu Granules for treatment of degenerative osteoarthritis. In addition, its product pipeline candidates comprise Jing Tong Ting, a phase III clinical trial product for menstrual pain; Da An Granules, a phase III ongoing product for anxiety; Yushuda Tablets, a phase III ongoing product for depression; and Dan Xian Kang Gu Capsules, a phase III design ongoing product for ischemic necrosis.

TopoTarget A/S company develops and markets anti-cancer drugs, as well as therapies for cancer-related conditions. Its portfolio includes preclinical candidates, drugs in clinical development, and marketed products. Its Savene therapy is sold in Europe and is a detoxifying drug which limits tissue damage after accidental exposure to certain chemotherapy agents; the drug is also marketed as Totect in the US. Founded in 2000, TopoTarget works with academic and commercial development partners in the US and Europe. Its biopharmaceutical candidates aim to fight cancers such as lymphoma, melanoma, and ovarian, breast, and neck cancers.

Transcept Pharmaceuticals, Inc. (Transcept) is a specialty pharmaceutical company focused on the development and commercialization of products that address important therapeutic needs in the field of neuroscience. The lead Transcept product candidate, Intermezzo, is a sublingual low dose formulation of zolpidem that has been developed for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep. The Company has completed all scheduled clinical trials on behalf of Intermezzo and submitted a New Drug Application (NDA), to the United States Food and Drug Administration (FDA), on September 30, 2008, which was accepted for filing on December 15, 2008. On January 30, 2009, Transcept completed a merger with Novacea, Inc. As part of the transaction, Novacea changed its name to Transcept Pharmaceuticals, Inc.

TRANSGENE S.A. company was founded in 1979 and is based in Strasbourg, France. Transgene S.A. is a subsidiary of Merieux Alliance. Transgene S.A., a biopharmaceutical company, engages in the discovery and development of gene-based therapeutic vaccines and immunotherapy products for the treatment of cancer and infectious diseases. The company’s products primarily include TG 4001/R3484, an immunotherapy targeting anti-infectious for human papilloma virus-associated pathologies, which completed Phase IIa trials; TG 4010, a cancer vaccine primarily for non small cell lung cancer, which is in Phase IIb trials; TG 1042, an immune enhancement gene therapy for cutaneous B-cell lymphoma, which is in Phase II trials; TG 4040, an anti-infectious therapeutic vaccine for chronic hepatitis C infection, which is in Phase I trials; and TG 4023, a preclinical suicide gene candidate for the treatment of 5-FU-sensitive tumors. It also offers a package of services relating to molecular biology, development, and biomanufacturing that include design and construction of new vaccines; development and/or adaptation of production process; development and/or adaptation of quality control assays; production and control of starting material for pharmaceutical and clinical development; and manufacturing material for clinical trials. Transgene S.A. has collaboration agreements with Roche, Association Francaise contre les Myopathies, and MIRUS; manufacturing and subcontracting agreements with International AIDS Vaccine Initiative, Innogenetics, Agence Nationale de Recherche contre le SIDA, Institut National de la Sante et de la Recherche Medicale, and EUROVACC; and licensing agreements with Merck, Imperial Cancer Research Technology, Ajinomoto, Aventis, and Cayla.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.